ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FLGT Fulgent Genetics Inc

20.10
0.07 (0.35%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Fulgent Genetics Inc NASDAQ:FLGT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.07 0.35% 20.10 19.71 32.00 20.32 20.00 20.03 77,988 05:00:01

Fulgent Genetics to Announce First Quarter 2019 Financial Results on Tuesday May 7, 2019

18/04/2019 1:00pm

GlobeNewswire Inc.


Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Fulgent Genetics Charts.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its first quarter 2019 financial results after the market closes on Tuesday May 7, 2019. The company’s Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 9394882. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 9394882 through May 14, 2019.

About Fulgent Genetics

Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Relations Contacts:The Blueshirt GroupNicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com

1 Year Fulgent Genetics Chart

1 Year Fulgent Genetics Chart

1 Month Fulgent Genetics Chart

1 Month Fulgent Genetics Chart

Your Recent History

Delayed Upgrade Clock